Cargando…
Tandem Mass Tag-Based Serum Proteome Profiling for Biomarker Discovery in Young Duchenne Muscular Dystrophy Boys
[Image: see text] Blood-accessible molecular biomarkers are becoming highly attractive tools to assess disease progression and response to therapies in Duchenne muscular dystrophy (DMD) especially in very young patients for whom other outcome measures remain subjective and challenging. In this study...
Autores principales: | Alayi, Tchilabalo D., Tawalbeh, Shefa M., Ogundele, Michael, Smith, Holly R., Samsel, Alison M., Barbieri, Marissa L., Hathout, Yetrib |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581259/ https://www.ncbi.nlm.nih.gov/pubmed/33110978 http://dx.doi.org/10.1021/acsomega.0c03206 |
Ejemplares similares
-
Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020) -
Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
por: Ogundele, Michael, et al.
Publicado: (2021) -
Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2019) -
Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys
por: Dang, Utkarsh J, et al.
Publicado: (2020) -
Clinical utility of serum biomarkers in Duchenne muscular dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2016)